{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-026156","form_type":"8-K","ticker":"NMRA","cik":"0001885522","company_name":"Neumora Therapeutics, Inc.","filed_at":"2025-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.480644+00:00","generated_at":"2026-05-26T22:25:44.733521+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Founder Berns becomes CEO as Gosebruch departs; option repricing approved","bullets":["Paul L. Berns transitions from executive chair to CEO & chairman, effective Feb 14, 2025.","CEO Henry Gosebruch and Chief Commercial Officer Kaya Pai Panandiker leave the company.","Joshua Pinto promoted to president (base $645k, 60% target bonus, $970k signing bonus, 3M option).","Bill Aurora becomes COO & CDO; Michael Milligan becomes CFO; other leadership changes announced.","Board approved option repricing subject to stockholder approval; exercise price set at Feb 13 closing price."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-026156","json":"https://secwatch.observer/filing/0001193125-25-026156.json","markdown":"https://secwatch.observer/filing/0001193125-25-026156.md","text":"https://secwatch.observer/filing/0001193125-25-026156.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1885522/000119312525026156/0001193125-25-026156-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1885522/000119312525026156/d932957d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T22:25:44.733521+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"15da3792c0","claim":"Joshua Pinto changed role as President at Neumora Therapeutics, Inc..","evidence_excerpt":"Joshua Pinto, Ph.D. will transition from the role of Chief Financial Officer to President","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1885522/000119312525026156/0001193125-25-026156-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"transitioned"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"475b2f90b6","claim":"Henry Gosebruch departed as President, Chief Executive Officer at Neumora Therapeutics, Inc..","evidence_excerpt":"Henry Gosebruch will depart the Company and no longer serve as President, Chief Executive Officer or a member of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1885522/000119312525026156/0001193125-25-026156-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"President, Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"613e0fbbd4","claim":"Carol Suh changed role as Chief Strategy Officer at Neumora Therapeutics, Inc..","evidence_excerpt":"Carol Suh will transition from the role of Chief Operating Officer to Chief Strategy Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1885522/000119312525026156/0001193125-25-026156-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"transitioned"},{"label":"Role","value":"Chief Strategy Officer"}],"fact_type":"executive_change"},{"claim_id":"995a74e38e","claim":"Bill Aurora changed role as Chief Operating and Development Officer at Neumora Therapeutics, Inc..","evidence_excerpt":"Bill Aurora, Pharm.D. will transition from the role of Chief Strategy Officer to Chief Operating and Development Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1885522/000119312525026156/0001193125-25-026156-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"transitioned"},{"label":"Role","value":"Chief Operating and Development Officer"}],"fact_type":"executive_change"},{"claim_id":"bcba4e24f6","claim":"Jason Duncan was appointed as Chief Legal and Administrative Officer at Neumora Therapeutics, Inc..","evidence_excerpt":"Jason Duncan will serve as Chief Legal and Administrative Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1885522/000119312525026156/0001193125-25-026156-index.htm","confidence":0.8,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Legal and Administrative Officer"}],"fact_type":"executive_change"},{"claim_id":"d57e56ad54","claim":"Kaya Pai Panandiker departed as Chief Commercial Officer at Neumora Therapeutics, Inc..","evidence_excerpt":"Kaya Pai Panandiker will depart the Company and no longer serve as Chief Commercial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1885522/000119312525026156/0001193125-25-026156-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"Chief Commercial Officer"}],"fact_type":"executive_change"},{"claim_id":"d914308747","claim":"Michael Milligan was appointed as Chief Financial Officer at Neumora Therapeutics, Inc..","evidence_excerpt":"Michael Milligan will serve as Chief Financial Officer in addition to his current role as principal accounting officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1885522/000119312525026156/0001193125-25-026156-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"ecebe75885","claim":"Paul L. Berns changed role as Chief Executive Officer and Chairman of the Board at Neumora Therapeutics, Inc..","evidence_excerpt":"Paul L. Berns, the Company’s Co-Founder and Executive Chairman of its Board of Directors (the “Board”), will transition to the roles of Chief Executive Officer and Chairman of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1885522/000119312525026156/0001193125-25-026156-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"transitioned"},{"label":"Role","value":"Chief Executive Officer and Chairman of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}